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Background: Targeted next-generation sequencing (NGS) is increasingly applied in
clinical oncology to advance personalized treatment. Despite success in many other
tumour types, use of targeted NGS panels for assisting diagnosis and treatment of head
and neck squamous cell carcinomas (HNSCC) is still limited.
Aim: The focus of this study was to establish a robust NGS panel targeting most frequent
cancer mutations in long-term preserved formalin-fixed paraffin-embedded (FFPE) tissue
samples of HNSCC from routine diagnostics.
Materials and Methods: Tumour DNA obtained from archival FFPE tissue blocks of
HNSCC patients treated at Haukeland University Hospital between 2003-2016 (n=111)
was subjected to mutational analysis using a custom made AmpliSeq Library PLUS panel
targeting 31 genes (Illumina). Associations between mutational burden and clinical and
pathological parameters were investigated. Mutation and corresponding
clinicopathological data from HNSCC were extracted for selected genes from the
Cancer Genome Atlas (TCGA) and used for Chi-square and Kaplan-Meier analysis.
Results: The threshold for sufficient number of reads was attained in 104 (93.7%) cases.
Although the specific number of PCR amplified reads detected decreased, the number of
NGS-annotated mutations did not significantly change with increased tissue preservation
time. In HPV-negative carcinomas, mutations were detected mainly in TP53 (73.3%),
FAT1 (26.7%) and FLG (16.7%) whereas in HPV-positive, the common mutations were inSeptember 2021 | Volume 11 | Article 7341341
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Frontiers in Oncology | www.frontiersin.orgFLG (24.3%) FAT1 (17%) and FGFR3 (14.6%) genes. Other less common pathogenic
mutations, including well reported SNPs were reproducibly identified. Presence of at least
one cancer-specific mutations was found to be positively associated with an extensive
desmoplastic stroma (p=0.019), and an aggressive type of invasive front (p=0.035), and
negatively associated with the degree of differentiation (p=0.041). Analysis of TCGA data
corroborated the association between cancer-specific mutations and tumour
differentiation and survival analysis showed that tumours with at least one mutation had
shorter disease-free and overall survival (p=0.005).
Conclusions: A custom made targeted NGS panel could reliably detect several specific
mutations in archival samples of HNSCCs preserved up to 17 years. Using this method
novel associations between mutational burden and clinical and pathological parameters
were detected and actionable mutations in HPV-positive HNSCC were discovered.Keywords: next-generation sequencing (NGS), actionable mutation, pathological parameters, stromal
desmoplasia, inflammation, head and neck squamous cell carcinoma (HNSCC)INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC), arising in
the oral cavity, oropharynx, hypopharynx and larynx, is a major
public health concern worldwide (1). The incidence and
mortality rates of HNSCC are increasing, with approximately
750,000 new cases and 360,000 deaths reported in 2020 (1).
HNSCC are characterized by aetiological, phenotypical,
biological, and clinical heterogeneity (2, 3). Smoking and
smokeless tobacco chewing habits in developing countries and
human papillomavirus (HPV) infection in developed countries
are emerging as important risk factors for the rise in incidence
rates of HNSCC (2, 3). Given the reported differences in survival
outcomes based on HPV and smoking status, establishing HPV
as a prognostic factor for better survival in oropharyngeal SCC
(OPSCC) (4, 5), there is an additional interest in understanding
the molecular differences between HPV-positive and HPV-
negative lesions especially in OPSCC.
Current cancer treatment is moving towards more
personalized and targeted treatment. Both targeted and
immunotherapies have improved 5-year survival rates
significantly in many types of cancers (6–8). However, for
patients with HNSCC the only targeted therapy approved is
cetuximab, a monoclonal antibody against epidermal growth
factor receptor (EGFR) (6, 9). Recently, pembrolizumab and
nivolumab, immunotherapeutic agents, have been approved for
HNSCC (10, 11). Nonetheless, patients treated with targeted
therapy such as cetuximab combined with radiotherapy develop
resistance (6, 12) and less than 20% of HNSCC patients treated
with immunotherapy achieve a lasting response (13).
Several studies have investigated genomic aberrations
associated with HNSCC and this has greatly increased our
understanding of the mutational landscape of HNSCC (2, 3,
14–16). Moreover, with the advent of next-generation
sequencing (NGS), several studies have added to the ever-
growing list of novel genetic alterations in HNSCC. Frequent
mutations in several genes including TP53, CDKN2A, PIK3CA,2
NOTCH1, CASP8 and MLL2 (KMT2D) among others as well
as alterations in EGFR, CCND1 and FGFR have been reported
(14–16). However, these genes are yet to translate into clinically
beneficial prognostic or predictive biomarkers. The incorporation
of NGS into routine clinical setting has been hampered by lack of
large number of biopsy specimens. Formalin-fixed paraffin-
embedded (FFPE) archival tissues could overcome this as they
are a rich resource that could allow correlations of specific
mutational landscape with clinical and pathological parameters
in long-term follow-up retrospective studies.
The aim of this study was to establish a robust NGS panel
targeting most frequent cancer mutations in long-term preserved
FFPE samples of HNSCC that would allow testing of clinical
outcome and correlations with clinical and pathological
parameters of cancer-specific mutations. This method could
serve for identification of novel, actionable mutations that
would open new avenues for personalized therapy in HNSCC.
In addition, it will also bring new insights into the biology of
this disease by allowing investigation of correlations between
mutational landscape of tumours, clinical variables, and
histopathological parameters, which is difficult to assess in
fresh-frozen tissues. In this study we report that a custom made
targeted NGS panel could reliably detect several specific mutations
in archival samples of HNSCCs preserved up to 17 years. Using
this method, we could identify targetable mutations in HNSCC
and reveal novel associations between the mutational load and
clinicopathological variables like tumour desmoplasia, pattern of
invasion at the tumour front and the degree of differentiation.MATERIALS AND METHODS
Patient Cohort
The cohort consisted of consecutive patients diagnosed with
HNSCC at the Department of Otolaryngology/Head & Neck
Surgery, Haukeland University Hospital (HUH), Bergen,
Norway between 2003 to 2010 and 2013 to 2016, who consentedSeptember 2021 | Volume 11 | Article 734134
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cancer-free control patients were enrolled in this retrospective
study. Due to insufficient number of reads, seven HNSCC patients
and two cancer-free controls were excluded from the final analysis.
Out of 104 patients with NGS data that passed the threshold of
reads, 43 (41.3%) patients were HPV-positive, 57 (54.8%) patients
were HPV-negative, and 4 (3.8%) were not tested for HPV.
Clinical data (age, gender, smoking, TNM staging at the point of
diagnosis according to the American Joint Committee on Cancer
(AJCC) manual 6th edition) was obtained from the Electronic
Patient Journal at Haukeland University Hospital (DIPS). To
ensure continuity in the study with respect to HNSCC
classification during the whole period (2003-2016), staging of all
the tumours has been set based on the AJCC 6th edition. The study
was approved by the Regional (REK Vest) Committee for Medical
and Health Research Ethics (2011/125).
Histopathological Evaluation of
Haematoxylin and Eosin (HE) Sections
All morphological evaluations were done on representative HE
sections from FFPE blocks by an expert pathologist (OKV) and a
specialist in surgery (HH). The morphological scoring was done
by consensus evaluation based on a pre-defined list of criteria and
without knowledge of the HPV status following the scoring system
described elsewhere (17, 18). The following tumour phenotypic
criteria were evaluated: a) degree of keratinization, b) fraction
maturating cells (%), and c) tumour stromal invasion pattern. In
addition, the following host response patterns to tumour were
evaluated: d) inflammatory response and e) stromal desmoplasia.
Each parameter was scored 1-4 and further defined in
Supplementary Table 1 in detail. Degree of keratinization was
defined as tumour area with apparent keratinized single cells,
groups of cells or areas with remnants of keratinized cells. Fraction
maturing cells was denoted as the fraction of immature (basal like
cells) cells relative to the more differentiated cell fraction in
the tumour sample. The invasion pattern was evaluated at the
interphase between tumour and the intervening stroma at the
invasive tumour front (19). The inflammatory host response was
evaluated as the extent of chronic inflammation denoted by the
presence of lymphocytes, plasma cells and histiocytic cells
surrounding the invading tumour front. Areas with neutrophil
granulocytic responses were not considered as these areas may
represent secondary host responses due to tumour cell death,
infection or ulcerations. Tumour stromal desmoplasia was
evaluated only in the context of fibrillary and myxomatous
tumour host responses i.e., the angiogenetic tumour host
responses was not included in this parameter.
DNA Isolation and HPV Detection
All tumour samples were reviewed, and representative tissue
samples were selected. DNA was extracted from FFPE tissue
blocks. These were tissues from primary HNSCC from diagnostic
or surgical samples collected 5 to 17 years ago. For the NGS
analysis at least 20% tumour fraction was required to be included
in the analysis. Many of FFPE blocks were macro-dissected to
enrich the tumour fraction of the patient samples. The mean
tumour fraction was 47.5% (median 50%) in the samples thatFrontiers in Oncology | www.frontiersin.org 3were analysed with NGS. Three to six 10 µm thick FFPE sections
were de-paraffinized in deparaffinization solution and digested
overnight in ATL-buffer and Proteinase K (Qiagen GmbH,
Hilden, Germany) at 56°C. DNA was extracted using the
E.Z.N.A tissue DNA kit (Omega BioTek, Norcross, GA, USA),
and the DNA concentration was quantified using Qubit dsDNA
BR assay kit (Thermo Fisher Scientific, Waltham, MA, USA)
according to manufacturer’s protocol.
HPV DNA detection was performed using standard Gp5+/
Gp6+ primers as described elsewhere (20, 21). p16 status of all
HPV-positive OPSCC from 2003-2010 (75% of cohort) was also
determined by performing immunohistochemistry (IHC) using
anti-p16INK4a monoclonal antibody (clone E6H4, Roche
diagnostics, Switzerland) as described elsewhere (5, 22). The
cut-off percentage for p16 positivity was set as 70% as described
in literature for OPSCC (5).
Design of Custom Made NGS Panel
The custom made NGS panel was based on previously reported
mutational burden in HPV-negative and HPV-positive HNSCC
(15, 23, 24). For some genes, the specific targeted regions were
adapted from the commercially available Illumina TruSight
Tumor 15 (TP53, NRAS) and TruSight Tumor 26 (AKT 1,
BRAF, CTNNB1, KIT, PTEN) NGS panels (Illumina, San
Diego, CA, USA). The PCR primer sets for the other targeted
gene regions were de novo annotated and designed by Illumina
DesignStudio. A custom-made NGS panel, targeting hotspot
gene exon regions in 28 genes and complete exon coverage in
3 genes (TP53, TRAF 3 and FAT1) was designed. The list of genes
is shown in Supplementary Table 2. Year- and side-matched
normal samples (n=7), samples with known specific mutations,
and Acrometrix oncology hotspot control (Thermo Fisher
Scientific, Waltham, CA, USA) were used for quality control of
the NGS panel.
NGS Library Preparation and Sequencing
DNA library preparation was conducted using the AmpliSeq
Library PLUS kit (Illumina, San Diego, CA, USA) according to
manufacturer’s instructions. Briefly, 50 ng of DNA was used to
prepare amplicon libraries with two custom-made primer pools.
The amplicons were then partially digested, ligated to AmpliSeq
CD indexes and purified with AMPure XP beads (Beckman
Coulter, High Wycombe, UK). Further, the library was again
amplified, purified with beads, and then quantified using Qubit
dsDNA HS kit (Thermo Fisher Scientific, Waltham, MA, USA).
Samples were pooled in equimolar concentrations, and finally 1.3
pM of library solution was loaded for paired-end sequencing on
the Illumina MiniSeq platform using the BaseSpace Sequence
Hub (Illumina, San Diego, CA, USA).
Bioinformatics
Bioinformatical analysis was performed using the DNA
amplicon v.2.1.1 workflow in BaseSpace (Illumina, San Diego,
CA, USA). The targeted regions (specified in a custom manifest
file) were aligned to the reference genome hg19/GRCh37
using the Burrows Wheeler Aligner. Variants were called using
the Somatic variant caller and annotated by RefSeq usingSeptember 2021 | Volume 11 | Article 734134
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database. An amplicon total depth (coverage) of more than
500 reads and a variant allele frequency (VAF) of more than
5% were set as strict thresholds to be included in the analysis. The
recorded variants were evaluated in dbSNP (National Centre for
Biotechnology Information) and the Cosmic (Catalog of Somatic
Mutations in Cancer) databases and only coding sequences were
considered (25). The European population frequencies for the
variants were found in the ALFA Allele Frequency Aggregator
(26). If a mutation had an allele frequency of more than 1% it was
considered a single nucleotide polymorphism (SNP). Mutations
with an allele frequency in the range 0.1% - 1% were also
considered a SNP unless they had a pathogenic score of more
than 0.5 in the Cosmic database. All mutations recorded were of
the non-synonymous type, but for SNPs synonymous mutations
were also recorded separately. Four normal FFPE tonsillar tissue
samples from the period 2003-2010 and three normal FFPE
tonsillar samples from the period 2012-2015 were analysed to
validate mutations with respect to unspecific variants due to very
aged FFPE tumour samples in this study.
Graphs related to mutational signatures were created using a
web based application: Mutational Signatures in Cancer (MuSiCa)
(27). Pictorial distribution of SNVs on protein domain structures
was plotted using cBioPortal online tool (28, 29).
Statistical Analysis
The statistical analysis was performed using IBM SPSS Statistics
Version 25.0 (Armonk, IBM Corp, USA). The data is presented
as mean ± SEM (standard error over mean) and significance set
at p<0.05. Tests of independence of clinicopathological
parameters with mutational burden were assessed using
Pearson’s chi-squared test and Phi correlation coefficient was
calculated to measure the strength of association between
variables tested. For correlation analysis, cases were categorized
into higher and lower mutational burden groups by mean value
or a pre-set cut-off point; pathological parameters were
dichotomized in lower (1&2) and higher scores (3&4).
Analysis of TCGA Data
Mutation status for TP53, FAT1, FLG, CDKN2A, FGFR3, NSD-1,
and KMT2C genes and corresponding clinicopathological data
for HNSCC (n=496) specimens were exported using cBioPortal
online tool (28, 29). The data were imported to IBM SPSS for
further statistical analysis. HNSCC were stratified with respect to
the mutational status of the examined genes and associations
between the mutational status and clinicopathological
parameters and 5-year overall survival or 5-year disease
(relapse) free survival were examined using Chi-square test,
and Kaplan-Meier plot (Log Rank test), respectively.RESULTS
Clinical Characteristics of the
HNSCC Cohort
The NGS data from the HNSCC cohort after quality control
consisted of 104 patients with SCC at different anatomical headFrontiers in Oncology | www.frontiersin.org 4and neck sites: oropharynx (61%), oral cavity (32%),
hypopharynx (3%), larynx (2%), and metastatic lymph nodes
(3%). The majority of cohort consisted of males (79%), the
median age was 63 years (range 38-87), and the majority
(68%) had a history of smoking. At the time of diagnosis,
61.5% presented with T1&T2 while 35.6% were at late T3&T4
stages, 54.8% had loco-regional lymph node metastasis, and 3%
had distant metastasis.
For determining the HPV status, both HPV DNA and IHC
for p16 were performed. The sensitivity and specificity of p16
IHC as compared to HPV DNA detection was 96% and 85.7%,
respectively. From all HNSCC cases, 43 (41.3%) were HPV-
positive as determined by presence of HPV DNA, with the
majority being oropharyngeal SCC (95.4%) and only 2% of
oral SCC being HPV-positive. Most of the HPV-positive
cancers presented with lymph node metastasis (79.1%) at
diagnosis, and only 38.6% of the HPV-negative. A positive
moderate correlation between HPV status and locoregional
lymph node metastasis was detected (p<0.001, r=0.422). In
addition, among the oropharyngeal cancers, 41 out of 63
(66.7%) were HPV-positive while the rest were HPV-negative
(33.3%). Out of these 41 HPV-positive cases, 24 cases (58.5) %
were T1 and T2 early-stage tumours and 33 cases (80.5%) had
lymph node metastasis (p=0.018, r=0.30). Clinical details of all
the patients are presented in Table 1.
Clinico-Pathological Correlations
Including all subsites of HNSCC, HPV-positive cases presented
with a non-aggressive tumour invasive front (p<0.001), little
desmoplastic stromal reaction (p=0.034), but rich inflammatory
host reaction (p<0.001) than the HPV-negative cases (Figure 1).
Most of the HPV-positive cases presented with a less
differentiated (p<0.001, r=0.570), basal like morphology
(p<0.001, r=0.363), and had a more pushing (non-aggressive)
border type of invasion front (p<0.001, r=-0.538). Consistent
with these observations, HPV-positive OPSCC showed non-
aggressive tumour invasive front (p=0.001), little desmoplastic
stromal reaction (p=0.059, borderline significant), and rich
inflammatory host reaction (p=0.013) than HPV-negative
OPSCC. In addition, HPV-positive OPSCC displayed a less
differentiated (p=0.003, r=0.378), and basal like morphology
(p=0.081, r=0.22). Bigger tumours (T3&T4) were associated
with a richer desmoplastic stroma (p<0.001, r=0.398), but with
a little inflammatory infiltrate (p=0.018, r=0.238). Extensive
stromal desmoplasia positively associated with an aggressive
tumour invasion front (p<0.001, r=0.426) and presence of
metastasis (p=0.045, r=0.203), but inversely associated with the
rich inflammatory infiltrate (p<0.001, r=0.-589). The presence of
a rich inflammatory infiltrate was negatively associated with an
aggressive type of invasive front (p=0.001, r=-0.330) (Figure 1).
Performance of the NGS Method on
FFPE Samples and the Effect of
Preservation Time
Of special concern was the performance of the targeted NGS
panel on aged FFPE material, especially in the FFPE tissue
samples preserved in the diagnostics biobank for longer thanSeptember 2021 | Volume 11 | Article 734134
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reads per amplicon in the longer time preserved group (2003-
2010) was 1709 (n=46) versus 1862 (n=58) in the shorter time
preserved group (2013-2016), compatible with some lower
coverage in the more aged FFPE tissue samples. Of the seven
cases that were excluded due to low coverage, five cases were
from 2003/04, one case from 2010 and one case form 2015,
indicating some concern with respect to performance due to
ageing of the FFPE material after more than 5 years preservation
time. The excluded cases had number of reads ranging from 20-
435 with a median of 159. Targeted sequencing of 101 tumours
and 3 tumours from metastatic sites resulted in a total of 2099
single nucleotide variations (SNVs) and 15 indels. No specific
difference was, however, noted with respect to SNPs or
mutational load between the older samples and the newer
ones, stored for 17 and 5 years, respectively.
Mutational Landscape of HNSCC as
Depicted by the Custom Made NGS Panel
The most frequently mutated genes in this Norwegian cohort of
HNSCC were TP53 (n=45, 43.3%), FAT1 (n=23, 22.1%), FLG
(n=20, 19.3%), CDKN2A (n=10, 9.6%), and FGFR3 (n=7, 6.7%)
(Figure 2). The tumour mutational burden (TMB), defined as
total number of non-synonymous mutations per coding area of
sequenced region, was 2.218 ± 0.2965 for the whole cohort.
Smokers displayed higher TMB as compared to non-smokers
(2.424 ± 0.4113 and 1.777 ± 0.2940, respectively), although the
difference was not statistically significant. TMB was significantly
higher in HPV-negative tumours (2.714 ± 0.4292) as compared
to HPV-positive (1.515 ± 0.3576, p=0.04). Among the HPV-
negative tumours, the highest TMB was detected in oral cavity
SCCs (3.239 ± 0.7423), as compared to oropharyngeal SCCs
(2.134 ± 0.3041, p=0.2471) (Figure 2A). Also, HPV-positive
OPSCC had lower TMB (1.526 ± 0.375) as compared toTABLE 1 | Clinical parameters of patients.
Characteristics All patients
n = 104 (%)
HPV-positive
n = 43 (%)
HPV-negative
n = 57 (%)
p-value
Age at diagnosis 63 59 64 0.381
Median (38-87) (38-87) (39-84)
Sex: 0.230
Male 82 (78.8) 36 (83.7) 42 (73.7)
Female 22 (21.2) 07 (16.3) 15 (26.3)
Tumour site: 0.0001*
Oral cavity 33 (31.7) 01 (2.3) 32 (56.1)
Oropharynx 63 (60.6) 41 (95.4) 22 (38.7)
Hypopharynx 03 (2.9) 01 (2.3) 01 (1.7)$
Larynx 02 (1.9) 00 02 (3.5)
Metastasis 03 (2.9) – –
Smoking: 0.137
Yes 71 (68.3) 25 (58.1) 42 (73.7)
No 33 (31.7) 18 (41.9) 15 (26.3)
T stage: 0.289
T1 and T2 64 (61.5) 25 (58.1) 39 (68.4)
T3 and T4 37 (35.6) 18 (41.9) 19 (31.6)
Unknown 03 (2.9) – –
N stage: 0.0001
N0 44 (42.3) 9 (20.9) 35 (61.4)
N+ 57 (54.8) 34 (79.1) 23 (38.6)
Unknown 03 (2.9) – –
M stage: 0.127
M0 98 (94.2) 43 (100) 55 (94.7)
M+ 03 (2.9) 0 03 (5.3)
Unknown 03 (2.9) – –
Stage grouping# –
Stage I 12 (11.5) 01 (2.3) 10 (17.5)
Stage II 19 (18.3) 03 (6.9) 16 (28.1)
Stage III 11 (10.6) 05 (11.7) 06 (10.6)
Stage IV 59 (56.7) 34 (79.1) 25 (43.8)
Unknown 03 (2.9)p-value is based on Chi-square test.
*Correlation between oral cavity and oropharynx based on HPV status. #Based on AJCC
6th edition. $HPV DNA test was inconclusive for one patient. Significant values are denoted
in bold.A B
FIGURE 1 | Clinico-pathological correlations depicting an extensive (scores 3&4) stromal reaction, an aggressive (scores 3&4) invasive front and a poor (scores 3&4)
inflammatory infiltrate in HPV-negative HNSCC as compared to the HPV-positive cases (A), and associations between extensive stromal reaction and bigger size
tumours, an aggressive invasive front, and a poor inflammatory infiltrate (B).September 2021 | Volume 11 | Article 734134
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difference in TMB in the two different types of sexes, female:
(2.1927 ± 0.448) and male: (2.2260 ± 0.357).
The mutational landscape of HPV-positive and HPV-
negative tumours was distinct. In HPV-negative carcinomas,
mutations were detected mainly in TP53 (73.3%), FAT1
(26.7%) and FLG (16.7%) whereas in HPV-positive, the
common mutations were in FLG (24.3%) FAT1 (17%) and
FGFR3 (14.6%) genes. A majority of TP53 mutations were
missense (66.7%) followed by nonsense (17.7%) mutations.
Frameshift indels (9%) were also frequently observed in the
TP53 gene. Interestingly, 20% (9/44) of the HPV-negative TP53
mutated tumours had more than one pathogenic TP53mutation.
Nearly 82% of FAT1 mutations were missense and only 8% were
nonsense, rest being frameshift indels. Inactivating mutations in
FAT1 (n=3) and CDKN2A (n=3) were exclusively found in HPV-
negative tumours. Contrary to this, genetic alterations in
fibroblasts growth factor receptor 3 (FGFR3), a potent
receptor-tyrosine kinases (RTK) involved in growth and
proliferation of cancer cells, were significantly higher in HPV-
positive vs. HPV-negative tumours (13.95% vs 1.73%, p=0.017).
All FGFR3 mutations were missense mutations. Notably the
mutations in genes encoding histone methyltransferases, NSD1
(5.8%) and KMT2C (5.8%) were reported, with majority of them
being missense. Commonly known mutations in RAS (3.9%,
combined for HRAS, NRAS and KRAS), CASP8 (3.8%), SMAD4
(3.8%), NOTCH2 (3.8%), and TRAF3 (3.8%) were also registered
(Figure 2B). Focussing only on OPSCC, most mutations in
HPV-positive OPSCC were FLG (22%) followed by FAT1
(17.1%), FGFR3 (14.6%) and NSD1 (9.8%). Notable mutations
in CASP8 and KMT2D (both 7.3%) were also found (Figure 2B).Frontiers in Oncology | www.frontiersin.org 6Mutational Signature of HNSCC
SNVs identified in the HNSCC cohort were further evaluated for
mutational signatures with respect to presence of HPV and
smoking status. The most common class of variant were
missense mutations in both HPV-negative and HPV-positive
tumours (Figure 3A). Also, the frequency of single nucleotide
polymorphisms (SNPs) was greater than insertions and deletions
both in HPV-positive and HPV-negative cases (Figure 3B).
Interestingly, more than 21% (13/60) of HPV-negative patients
had two mutations in the same gene as compared to only 7.3%
(3/41) patients in HPV-positive subtype (Figure 3C). As
reported before (30), C>T transitions were the most common
SNV type in both HPV-negative and HPV-positive tumours,
with the frequency being greater in the HPV-positive tumours
(Figures 3D, E).
Similar observations were made in smokers and non-smokers
subtypes with missense mutations being the most common class
of variant (Figure 4A). Also, the frequency of SNVs was
greater than other types of variants in smokers (Figure 4B).
Surprisingly, the percentage of patients having two mutations in
the same gene was more in non-smokers as compared to smokers
(Figure 4C). Based on the mutational signature, smokers had
higher frequency of C>T transitions among different SNVs, as
compared to non-smokers (Figures 4D, E).
Potentially targetable mutations in FGFR3 were identified.
Well established canonical missense mutations in R248C and
S249C were identified in five patients (4.8%) (Figure 5).
Surprisingly, all five patients were HPV-positive oropharyngeal
SCC with lymph node metastasis. These mutations are used as
predictive biomarkers for the use of erdafitinib in patients with
locally advanced or metastatic urothelial and bladder carcinomasA
B
FIGURE 2 | (A) Mutational burden and (B) mutational spectrum of head and neck squamous cell carcinomas as detected by targeted sequencing. Samples were
stratified according to HPV status followed by smoking status. Gene list is shown on the left whereas the corresponding frequency of mutation is shown on the right.
Pos- positive; Neg- negative.September 2021 | Volume 11 | Article 734134
Dongre et al. Molecular Landscape and Pathological Parameters(NCT02365597). The mutations have been proposed to activate
the FGF-receptor via ligand-independent dimerization by
generating novel cysteine residues (31, 32). Further, differentFrontiers in Oncology | www.frontiersin.org 7SNVs in proteins coding for FAT1 and NSD1 genes are also
shown in Figure 5. However, the distribution is of FAT1 and
NSD1 is heterogenous and does not point to any specific pattern.A B C
D
E
FIGURE 3 | Mutational signature in the HNSCC samples stratified with respect to HPV status for (A) variant classification and (B) variant type. (C) Comparison of
number of patients with two or more mutations in the same gene. Mutational profile based on C:G>T:A transitions in (D) HPV-negative and (E) HPV-positive samples.A B C
D
E
FIGURE 4 | Mutational signature associated with smokers and non-smokers based on (A) variant classification, and (B) variant type. (C) Comparison of number of
patients with two or more mutations in the same gene based on smoking status. Mutational profile based on C:G>T:A transitions in (D) smokers and (E) non-smokers.September 2021 | Volume 11 | Article 734134
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Cancer-Specific Mutations and
Clinico-Pathological Parameters
A higher number of cancer-specific mutations were associated
with a negative HPV status (p<0.001, r=0.448). No association
was observed between the number of SNPs per Mb detected and
HPV status or any other clinic-pathological parameters tested.
For the whole cohort, presence of at least one cancer-specific
mutation was found to be positively associated with an aggressive
type of invasive front (p=0.035, r=0.210), and extensive
desmoplastic stroma (p=0.019, r=0.234), and negatively
associated with the degree of differentiation (p=0.041,
r=-203) (Figure 6).
Validation of Correlations Between
Mutational Burden and Clinico-
Pathological Parameters in TCGA Dataset
The Chi Square analysis between mutational score reflecting the
presence of at least one mutation in any of the seven most
frequently cancer-specific mutated genes identified in our panel
(TP53, FAT1, FGF3, FLG, CDKN2A, KMT2C, and NSD1) and
clinicopathological variables available in the TCGA data set for
HNSCC showed that the mutation score was significantlyFrontiers in Oncology | www.frontiersin.org 8associated negatively with differentiation (p<0.001), and
positively with perineural invasion (p=0.010), and clinical
T-stage (p<0.001). The survival analysis showed that tumours
with at least one mutation in one of these genes had shorter 5-
year disease-free and overall survival (p=0.005 for both, Log
Rank) (Figure 7). Further, based on HPV-status stratification, it
can be observed that the seven gene panel predicts better disease-
free and overall survival in HPV-negative HNSCC (Figure 7).DISCUSSION
Formalin-fixed paraffin-embedded (FFPE) tumour tissue
samples are less optimal for NGS based applications than fresh
tissue samples. A major problem is cytosine deamination to
uracil, smaller insert sizes, higher duplication rates and an
increased frequency of falsely mapped SNVs. Still, Sweiger
et al. could show successful low coverage sequencing and copy
number detection in FFPE tissue samples stored for more
than 18 years (33). Significant improvements were made by
Hedegaard and co-workers to improve the output of NGS
whole exome sequencing in aged FFPE tissue material,
however the successful sequencing was obtained in only 29,5%FIGURE 5 | Pictorial representation of single nucleotide variant distribution on domain structure of FGFR3, FAT1 and NSD1.September 2021 | Volume 11 | Article 734134
Dongre et al. Molecular Landscape and Pathological Parametersof the samples (34). They noted in particular an increase in false
positive SNVs in FFPE tissue after prolonged storage for more
than 3-4 years (34). A similar observation has also been made by
others (35). On the other hand, Kerick and co-workers have
shown that smaller targeted NGS panels using PCR amplification
and an increased coverage will reduce the impact of FFPE
induced false positive SNVs in the work up of NGS analysis
(36). Our study has used long-term preserved (range 4-17 years)
FFPE tumour tissue samples for the NGS analysis. To reduce the
impact of fixation, the NGS library was re-amplified before
paired-end sequencing on the Illumina MiniSeq platform
based on manufacturer’s suggestion to improve number of
reads per sample. Also, a robust cut-off of 500 reads for total
allelic depth was used to minimize the risk of false positive SNVs
due to aged FFPE tumour tissue in our study. We have tested all
mutations/annotations involving C-T and A-G conversions in
the period 2003-2010 and 2013-2016 without finding significant
differences between these time periods. With these limitations
kept in mind, the study presents data on the application of a
custom-made, HNSCC targeted NGS panel using FFPE material
preserved for up to 17 years in a routine diagnostic pathology
service. We used the targeted NGS panel to characterize the
mutational landscape of a cohort of HNSCC patients with tissues
preserved at the Diagnostics Biobank at Department of
Pathology, Haukeland University Hospital. Our results are in
line with previous studies that found higher TMB in HPV-
negative cancers compared to HPV-positive HNSCC (14, 16).
In addition, the panel of genes found most frequently
mutated in our study is comparable to the findings from
previous studies performed using whole exome sequencing
(WES) (14–16). Due to strict cut-off of 500 reads, similar toFrontiers in Oncology | www.frontiersin.org 9what is used in diagnostics at HUS, several well reported
mutations in the PIK3CA/PTEN pathways were excluded from
the final analysis. However, from the remaining detected genes,
of interest is our finding of frequent mutations in the gene
encoding Nuclear Set Domain Containing Protein 1 (NSD1), a
histone methyltransferase, in both HPV-positive and negative
HNSCC. NSD1 has been identified as a biomarker for global
epigenetic changes in cancer (37, 38) and based on TCGA data, it
was recently suggested as a prognostic biomarker in patients with
HPV-negative HNSCC (39). Using TCGA data, Bui et al.
identified a survival advantage for patients with mutations in
the NSD1 gene. This gene was found altered in approximately
10% of patients with HNSCC, and they proposed that patients
with loss-of-function NSD1 mutations should be considered a
distinct clinical subclass of HPV-negative HNSCC, with
increased cisplatin sensitivity (39). In addition, we found
mutations in FGFR3 gene, particularly at R248C and S249C
that could be used as a targeted therapy especially in HPV-
positive HNSCC. Combined together, such findings are usually
the result of WES studies and are not prone to be further
implemented in the clinical oncology. However, WES is not
available at most hospitals owing to its high cost, operational
complexity, and long turnover times. On the other hand, lower-
cost targeted NGS for cancer specific genes are increasingly
affordable and finding its application in clinical oncology. We
show here that using a targeted NGS panel is an effective and
more affordable way for detecting actionable mutations in
archival material preserved for more than 17 years. Moreover,
novel mutations unearthed in FGFR3 in HPV-positive OPSCC
justifies the use of NGS based gene panel and suggest valid
targets in personalized treatment.A B
C
FIGURE 6 | Correlations of mutational landscape with histopathological parameters. (A) Bar graph showing distribution of cases with at least one mutation and
without mutations in the genes targeted by the NGS panel according to histopathological parameters. (B) Histological picture of a tumour with at least one mutation
detected by targeted NGS panel, and an extensive stromal desmoplastic response (solid arrows), an aggressive invasive tumour front (solid arrowheads), a less
differentiated phenotype and a poor inflammatory response. (C) Histological representation of a tumour with no mutations detected by targeted NGS panel and a little
stromal desmoplastic response, non-aggressive invasive tumour front (solid arrowheads), a more differentiated phenotype and an intense inflammatory response (solid
arrows). Scale bar = 100 mm.September 2021 | Volume 11 | Article 734134
Dongre et al. Molecular Landscape and Pathological ParametersWe further wanted to investigate possible association between
the presence of mutations in any of the genes investigated and
clinical and histopathological parameters. Histopathological
assessment of FFPE tissue and surgical resections still remains
the cornerstone of diagnosis and are readily available to a
pathologist with simple chemical stains. Not only this, but it is
well known fact that DNAmutations and their impact on cellular
mRNA and protein expression are the main drivers of changes
that are evident in the histopathological assessment. As reported
in this study, the presence of at least one cancer-specific
mutation among the seven most altered genes was associated
with less differentiation, an aggressive type of invasive front and aFrontiers in Oncology | www.frontiersin.org 10extensive desmoplastic stroma. To our knowledge, this is the first
attempt to study and identify associations between mutational
load and its stromal host response. In the light of the recent
development of immunotherapy, mutational landscape has been
previously investigated as a predictor of immune response, but
the stromal response has not been investigated in this respect.
TMB has been reported as a biomarker for predicting response to
immunotherapy in cancer patients (40, 41). This seems to be
explained by the thought that tumours with high TMB express a
greater diversity of neoantigens, resulting in increased immune
recognition when immune checkpoint inhibitors release natural
brakes on the immune system. Of note, we did not identify anyFIGURE 7 | Kaplan-Meier curves showing significant associations between the mutational score based on seven cancer-specific genes found most frequently
mutated in HNSCC and further stratified based on HPV-status using the targeted NGS panel and disease-free survival (5 years) and overall survival (5 years).September 2021 | Volume 11 | Article 734134
Dongre et al. Molecular Landscape and Pathological Parameterscorrelations between TMB or presence of mutations in the
investigated genes and presence of a heavier immune infiltrate,
but correlations with a more aggressive type of invasion and
fibroblastic stromal response were found.
Looking more into the histopathological variables, we have
revealed a correlation between presence of at least one cancer
specific-mutation and a more desmoplastic response and an
aggressive type of invasion at the tumour front but less
inflammatory infiltrate. With the new knowledge on the role of
cancer associated fibroblasts (CAF) on inducing an immune
suppressive phenotype in HNSCC (42) our findings are not
surprising. Takahashi et al. found CAFs from HNSCC to express
higher B7H1 (PDL1) and B7DC (PDL2) than normal fibroblasts,
both putative negative regulators of immune function.
Functionally, they were able to suppress T cell proliferation,
induce T cell apoptosis and recruit Treg (CD4+Foxp3+) cells.
Subpopulations of CAFs with immunosuppressive functions
have been recently described in other cancer tissues as well
(43). In this respect it is also worth mentioning that our analysis
revealed that the HPV-positive cases presented with a non-
aggressive tumour invasive front, little desmoplastic stromal
reaction, but rich inflammatory host reaction than the HPV-
negative cases. This indicates a differential host response to
HPV-positive cancers compared to HPV-negative.
The findings of this study were validated on an independent
data set. Using TCGA data available for HNSCC, we found that
the presence of mutations in at least one of the seven most
frequently mutated genes identified by the NGS panel was
significantly associated with less differentiation, perineural
invasion, and clinical T stage. In addition, we could also
perform survival analysis on TCGA data since these data were
not available for our HNSCC cohort. The survival analysis
showed that tumours with at least one mutation in one of
these genes had a shorter 5-year disease-free and overall
survival, indicating a clinical relevance for the panel of genes
identified by the targeted NGS panel.CONCLUSIONS
A custom made targeted NGS panel could reliably detect several
specific mutations in archival samples of HNSCCs within 17
years of preservation. Using this method, novel associations
between mutational burden and clinical and pathological
parameters were detected and actionable mutation in HPV-
positive HNSCC were discovered. A specific focus was on NGS
data obtained on preserved FFPE material, especially with
respect to number of PCR amplified reads with a strict cut-off,
to uncover more novel and translational mutations.Frontiers in Oncology | www.frontiersin.org 11DATA AVAILABILITY STATEMENT
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